KVV E-Modules - Preformulation blueprint for solid oral dosage forms: Case driven insights into challenges, solutions, and advanced characterization

Quadrant -I (Video)

Preformulation blueprint for solid oral dosage forms: Case driven insights into challenges, solutions, and advanced characterization

Quadrant - II (Study Material)

1. Preformulation blueprint for solid oral dosage forms: Case driven insights into challenges, solutions, and advanced characterization

Quadrant - III (Assignments)

1. Preformulation blueprint for solid oral dosage forms: Case driven insights into challenges, solutions, and advanced characterization

1. Explain the role of preformulation studies in the development of solid oral dosage forms (SODF). 2. Discuss the Ritonavir (Norvir®) polymorphism case study as an example of preformulation challenges in pharmaceutical development. 3. Describe the common challenges encountered during formulation of solid oral dosage forms and the role of advanced characterization tools in addressing them.

Quadrant - IV (MCQs)

Q1. Preformulation studies are primarily carried out to:

A: Reduce tablet size B: Select packaging material C: Understand drug properties before formulation C: Increase production speed

Q2. Which of the following best defines preformulation?

A: Tablet coating process B: Evaluation of drug properties before dosage form design C: Final quality control testing D: Marketing authorization process

Q3. The Ritonavir case highlights the importance of studying:

A: Tablet hardness B: Drug color and appearance C: Solid-state polymorphism D: Taste masking

Q4. Poor powder flow during tableting most commonly leads to:

A: Capping B: Weight variation C: Chemical degradation D: Tablet discoloration

Q5. Which test is a simple indicator of powder flowability?

A: Dissolution test B: Angle of repose C: Stability chamber study D: Bioavailability study

Q6. Which property helps predict moisture-related stability problems?

A: pKa B: Particle shape C: Hygroscopicity D: Melting point

Q7. XRPD is primarily used to study:

A: A. Drug solubility B: B. Tablet hardness C: C. Crystalline and amorphous forms D: D. Excipient compatibility

Q8. Advanced characterization tools are mainly used when:

A: Routine tests give clear results B: API behavior is complex or unexplained C: Tablets fail visual inspection D: Manufacturing is complete

Q9. A tablet formulation shows acceptable dissolution initially but fails after storage. XRPD reveals appearance of a new peak. The …

A: Increase in particle size B: Moisture-induced polymorphic conversion C: Tablet over-lubrication D: Incorrect pH of dissolution medium

Q10. An API shows poor flow, high Carr’s index, and high Hausner ratio. Which preformulation decision is MOST appropriate?

A: Increase compression force B: Proceed directly to coating C: Modify particle properties or use granulation D: Skip preformulation and optimize excipients

Validation Certificates

No materials available.